Surgical or Medical Treatment

Youth-onset type 2 diabetes (T2D) leads to early dependence on exogenous insulin and progression of T2D co-morbidities, including dyslipidemia, hypertension, non-alcoholic fatty liver disease and diabetic kidney disease. The pathophysiology of T2D in youth differs considerably from adults and current treatment approaches are in-adequate for youth. Thus, exploration of innovative approaches to reduce co-morbidities is critical. Metabolic bariatric surgery (MBS) significantly improves multiple outcomes in adults with T2D. Initial small, uncontrolled studies of Roux-en-Y gastric bypass also suggest beneficial effects in youth with T2D, but definitive studies and understanding of mechanisms in youth-onset T2D are lacking, especially with the now more common form of MBS, vertical sleeve gastrectomy (VSG).

We will test the hypothesis that VSG will be more effective in reducing glycemia and comorbidities than the best currently available medical treatment: advanced medical therapy (AMT), via pancreatic, enterohepatic and/or metabolic changes. To test this hypothesis, 90 adolescents with T2D will be studied to compare the effects of VSG vs. AMT on glycemic control and T2D-associated comorbidities, as well as underlying mechanisms.

Inclusion criteria

for the medical or surgical type 2 diabetes groups

• Age 13-19.9 years of age at time of signing the consent
• Type 2 diabetes by the American Diabetes Association criteria
• Negative diabetes-associated antibodies

Exclusion criteria

for the medical or surgical type 2 diabetes groups Known type 1 diabetes, maturity onset diabetes of the young (MODY), or secondary diabetes

• Any chronic oral steroids use within 60 days of enrollment
• Current pancreatotoxic drugs
• Chronic kidney or liver disease (except NAFLD or DKD)
• Pregnancy, breast-feeding or intension of becoming pregnant
• Prior bariatric surgery
• History of malignancy
• Current participation in another clinical trial that may affect study outcomes
• Other conditions, that in the determination of the study investigator, may interfere with study participation
• Inclusion Criteria for the Obese control group
• Age 13-19.9 years of age at time of signing the consent
• Clinical indication to receive bariatric surgery

Exclusion criteria

for the obese control group

• Known diabetes
• Any chronic oral steroids use within 60 days of enrollment
• Current pancreatotoxic drugs
• Chronic kidney or liver disease (except NAFLD or DKD)
• Pregnancy, breast-feeding or intension of becoming pregnant
• Prior bariatric surgery
• History of malignancy
• Current participation in another clinical trial that may affect study outcomes
• Other conditions, that in the determination of the study investigator, may interfere with study participation